Terms: = Leukemia AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Prognosis
189 results:
1. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.
Miao X; Shuai Y; Han Y; Zhang N; Liu Y; Yao H; Wang X; He G; Chen D; Fan F; Chang AH; Su Y; Yi H
Front Immunol; 2024; 15():1389227. PubMed ID: 38803489
[TBL] [Abstract] [Full Text] [Related]
2. Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China.
Yu W; Huang L; Mei H; Li Y; Niu T; Zou D; Liu Y; Zhang H; Liu P; Wu J; Wang Z; Li H; Cai Q; Mi JQ
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38802271
[TBL] [Abstract] [Full Text] [Related]
3. Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics.
Li H; Wang Y; Liu R; Li X; Zhang P; Chen P; Zhao N; Li B; Wang J; Tang Y
J Transl Med; 2024 May; 22(1):482. PubMed ID: 38773607
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive analysis of the efficacy and safety of car T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR
Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799
[TBL] [Abstract] [Full Text] [Related]
5. Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits.
Frankel NW; Deng H; Yucel G; Gainer M; Leemans N; Lam A; Li Y; Hung M; Lee D; Lee CT; Banicki A; Tian M; Almudhfar N; Naitmazi L; Roguev A; Lee S; Wong W; Gordley R; Lu TK; Garrison BS
Cell Rep; 2024 May; 43(5):114145. PubMed ID: 38669141
[TBL] [Abstract] [Full Text] [Related]
6. Sequential CD7 car T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Hu Y; Zhang M; Yang T; Mo Z; Wei G; Jing R; Zhao H; Chen R; Zu C; Gu T; Xiao P; Hong R; Feng J; Fu S; Kong D; Xu H; Cui J; Huang S; Liang B; Yuan X; Cui Q; Guo H; Yu Y; Feng Y; Jin C; Ren J; Chang AH; Wang D; Huang H
N Engl J Med; 2024 Apr; 390(16):1467-1480. PubMed ID: 38657244
[TBL] [Abstract] [Full Text] [Related]
7. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.
Dabkowska A; Domka K; Firczuk M
Front Immunol; 2024; 15():1363102. PubMed ID: 38638442
[TBL] [Abstract] [Full Text] [Related]
8. [CHIMERIC ANTIGEN RECEPTOR T CELLS (car-T CELLS) THERAPY FOR B-CELL HEMATOLOGICAL MALIGNANCIES - FROM THE ISRAELI SOCIETY OF HEMATOLOGY AND TRANSFUSION MEDICINE].
Greenbaum U; Yehudai-Ofir D; Beyar Katz O; Shargian L; Jacoby E; Grisaru S; Zuckerman T; Ram R; Avigdor A
Harefuah; 2024 Apr; 163(4):236-243. PubMed ID: 38616634
[TBL] [Abstract] [Full Text] [Related]
9. A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens.
Xiong ZY; Shen YJ; Zhang SZ; Zhu HH
Hematology; 2024 Dec; 29(1):2335856. PubMed ID: 38581291
[TBL] [Abstract] [Full Text] [Related]
10. Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 car-T cells bridging to haploidentical stem cell transplantation.
Song Y; Liu Z; Wang Q; Gao K; Wu T
Front Immunol; 2024; 15():1333037. PubMed ID: 38481998
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic leukemia After Anti-CD19 car T-Cell Therapy Without Bridging Transplantation.
Shang Q; Xue L; Lu A; Jia Y; Zuo Y; Zeng H; Zhang L
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):392-399.e5. PubMed ID: 38429221
[TBL] [Abstract] [Full Text] [Related]
12. [Clinical Analysis of Philadelphia Chromosome-Like Acute Lymphoblastic leukemia in Children].
Li TD; Hu SY; Zhai Z; Chen GH; Lu J; He HL; Xiao PF; Li J; Wang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):78-84. PubMed ID: 38387903
[TBL] [Abstract] [Full Text] [Related]
13. [Clinical features and prognostic analysis of testicular relapse in pediatric acute lymphoblastic leukemia].
Wang N; Gao YY; Qi BQ; Ruan M; Lyu H; Zhang XY; Zhang RR; Liu TF; Chen YM; Zou Y; Guo Y; Yang WY; Zhang L; Zhu XF; Chen XJ
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(3):262-267. PubMed ID: 38378289
[No Abstract] [Full Text] [Related]
14. Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
Kutsch N; Gödel P; Voltin CA; Hallek M; Scheid C; Borchmann P; Holtick U
Eur J Haematol; 2024 Jun; 112(6):984-987. PubMed ID: 38316549
[TBL] [Abstract] [Full Text] [Related]
15. Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience.
Qin S; Jiang R; Dai L; Miao Y; Sha Y; Qiu T; Ding C; Wang Z; Shi C; Xia Y; Fan L; Xu W; Li J; Zhu H
Ann Hematol; 2024 May; 103(5):1635-1642. PubMed ID: 38246951
[TBL] [Abstract] [Full Text] [Related]
16. Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of car-T-cell therapy.
Lin M; Zhao X; Chang Y; Zhao X
Chin Med J (Engl); 2024 Jan; 137(2):140-151. PubMed ID: 38148315
[TBL] [Abstract] [Full Text] [Related]
17. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.
Chiba M; Shimono J; Suto K; Ishio T; Endo T; Goto H; Hasegawa H; Maeda M; Teshima T; Yang Y; Nakagawa M
Blood; 2024 Apr; 143(14):1379-1390. PubMed ID: 38142436
[TBL] [Abstract] [Full Text] [Related]
18. Favorable response of a patient with primary B/myeloid mixed phenotype acute leukemia to CD19-car-T: Case report and literature review.
Wang L; Pang Y; Fang C; Zhao W; Xu Y; Guo X; Qiao J; Mei J; Wang H; Yu C; Li Y; Tang Z; Yu L
Medicine (Baltimore); 2023 Dec; 102(50):e36397. PubMed ID: 38115347
[TBL] [Abstract] [Full Text] [Related]
19. Broadening the horizon: potential applications of car-T cells beyond current indications.
Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
[TBL] [Abstract] [Full Text] [Related]
20. [car-T therapy for pediatric acute lymphoblastic leukemia].
Sakaguchi H
Rinsho Ketsueki; 2023; 64(11):1440-1446. PubMed ID: 38072432
[TBL] [Abstract] [Full Text] [Related]
[Next]